Investor Overview

Corporate Profile
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Company’s NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Company’s third-party licensees.
RGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$27.10
Change (%) Stock is Down 0.45 (1.63%)
Volume243,146
Data as of 01/19/18 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: RGNX.O.  Currently trading at $27.10 with a 52 week high of $36.45 and a 52 week low of $16.30.
Recent NewsMore >>
DateTitle 
01/08/18REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA Amended agreement permits assignment by AveXis upon a change of control without REGENXBIO’s consent REGENXBIO could receive up to $260 million, including $140 million in guaranteed upfront and annual payments              ROCKVILLE, Md. and CHICAGO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX) and AveXis, Inc. (Nasdaq:AVXS) today announced that they have enter... 
Printer Friendly Version
01/04/18REGENXBIO Provides Year-End 2017 Corporate Update
- Initiated third cohort dosing of RGX-314 Phase I clinical trial for wet AMD - - Initiated second cohort dosing of RGX-501 Phase I/II clinical trial for HoFH - - Anticipate completing dosing and presenting topline data from RGX-314 and RGX-501 trials in late 2018 - - Anticipate initiating dosing in clinical trials for MPS I and MPS II in first half 2018 - - Ended 2017 with greater than $175 million in cash, cash equivalents and marketable securities - ROCKVILLE, Md., Jan. 04, 2018 (GLOB... 
Printer Friendly Version
12/19/17REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II
Novel, one-time, direct-to-CNS treatment for MPS II focused toward potentially preventing the progression of cognitive deficits Clinical trial expected to enroll children with MPS II Anticipate beginning trial enrollment during the first half of 2018 ROCKVILLE, Md., Dec. 19, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technolog... 
Printer Friendly Version
11/22/17REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 22, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following November investor conferences: Evercore ISI Biopharma Catalyst/Deep Dive Conference Date: Wednesday, November 29, 2017 Location: Boston Harbor Hotel at Rowes Wharf Fireside chat: Wednesday... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Presentations
DateTitle
01/08/18
Corporate PresentationDownload Documentation 
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever REGENXBIO posts new information to the site. Just enter your e-mail address and click Submit.